KRAS-mutated tumours typically demonstrate an immunosuppressive TME, with secretion of immunosuppressive inflammatory cytokines, infiltration of immunosuppressive immune cells, and higher levels of PD-L1 expression (124). This evidence concerns the gene KRAS and neoplasm.